Insider Selling: Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) EVP Sells $166,649.60 in Stock

Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) EVP Joseph Baroldi sold 4,006 shares of the business’s stock in a transaction dated Tuesday, April 16th. The stock was sold at an average price of $41.60, for a total transaction of $166,649.60. Following the transaction, the executive vice president now owns 19,631 shares in the company, valued at approximately $816,649.60. The transaction was disclosed in a legal filing with the SEC, which is accessible through the SEC website.

Ionis Pharmaceuticals Price Performance

NASDAQ:IONS opened at $40.68 on Friday. The firm has a market cap of $5.93 billion, a PE ratio of -15.89 and a beta of 0.39. Ionis Pharmaceuticals, Inc. has a 12 month low of $34.32 and a 12 month high of $54.44. The company has a quick ratio of 5.83, a current ratio of 5.90 and a debt-to-equity ratio of 3.18. The company’s 50-day moving average price is $43.86 and its two-hundred day moving average price is $47.28.

Ionis Pharmaceuticals (NASDAQ:IONS) last released its quarterly earnings results on Wednesday, February 21st. The company reported ($0.06) EPS for the quarter, beating analysts’ consensus estimates of ($0.78) by $0.72. The firm had revenue of $325.00 million for the quarter, compared to analyst estimates of $176.01 million. Ionis Pharmaceuticals had a negative net margin of 46.32% and a negative return on equity of 90.29%. The company’s revenue for the quarter was up 113.8% compared to the same quarter last year. During the same period in the previous year, the business earned ($0.37) earnings per share. On average, equities analysts anticipate that Ionis Pharmaceuticals, Inc. will post -4 EPS for the current fiscal year.

Hedge Funds Weigh In On Ionis Pharmaceuticals

A number of large investors have recently modified their holdings of the stock. Diversified Trust Co acquired a new position in shares of Ionis Pharmaceuticals during the first quarter worth approximately $261,000. Sunbelt Securities Inc. acquired a new position in shares of Ionis Pharmaceuticals during the first quarter worth approximately $44,000. International Assets Investment Management LLC lifted its position in shares of Ionis Pharmaceuticals by 2,048.9% during the first quarter. International Assets Investment Management LLC now owns 7,607 shares of the company’s stock worth $334,000 after purchasing an additional 7,253 shares in the last quarter. Mather Group LLC. acquired a new position in shares of Ionis Pharmaceuticals during the first quarter worth approximately $29,000. Finally, Kapitalo Investimentos Ltda acquired a new position in shares of Ionis Pharmaceuticals during the fourth quarter worth approximately $289,000. 93.86% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

IONS has been the topic of several research reports. Bank of America upgraded shares of Ionis Pharmaceuticals from a “neutral” rating to a “buy” rating and boosted their price objective for the stock from $52.00 to $62.00 in a report on Tuesday, January 2nd. JPMorgan Chase & Co. upped their target price on shares of Ionis Pharmaceuticals from $52.00 to $55.00 and gave the company a “neutral” rating in a research note on Thursday, February 1st. Oppenheimer upped their target price on shares of Ionis Pharmaceuticals from $72.00 to $75.00 and gave the company an “outperform” rating in a research note on Tuesday, April 9th. StockNews.com raised shares of Ionis Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Saturday, February 24th. Finally, William Blair reissued an “outperform” rating on shares of Ionis Pharmaceuticals in a research note on Tuesday, April 9th. One research analyst has rated the stock with a sell rating, four have issued a hold rating, eight have issued a buy rating and one has given a strong buy rating to the stock. According to MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $56.08.

Ionis Pharmaceuticals Company Profile

Ionis Pharmaceuticals, Inc discovers and develops RNA-targeted therapeutics in the United States. The company offers SPINRAZA for spinal muscular atrophy (SMA) in pediatric and adult patients; TEGSEDI, an antisense injection for the treatment of polyneuropathy caused by hereditary transthyretin amyloidosis in adults; and WAYLIVRA, an antisense medicine for treatment for familial chylomicronemia syndrome (FCS) and familial partial lipodystrophy.